The EBRD is lending €20 million to a leading Ukrainian pharmaceuticals manufacturer, JSC Farmak, under its €2 billion Resilience and Livelihoods Framework supporting countries affected by russia’s war against Ukraine.
The financing, which will provide working capital to a manufacturer with a 5.7% pre-war share of Ukraine’s pharmaceuticals market, will support production and improve access to essential medicines for people living in Ukraine. This financing like all projects under the Framework, the EBRD will share risk with partners. First loss risk guarantee of 5.5% will be provided through the EBRD’s Shareholder Special Fund Risk Sharing Programme.
On the basis of both guarantees, total donor guarantee will cover 50% of the loan amount. Supporting the pharmaceutical sector during the war is a key element of Bank’s five-pronged support plan for the real economy of Ukraine and the surrounding region. The EBRD is also supporting trade, energy security, vital infrastructure and food security.
Follow us on Facebook, Twitter, LinkedIn, or YouTube .
